Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0001628280-26-015769 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-06 | 2026-03-04 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +15.0K | 163.5K | +10% | $0 |
| D | 2026-03-06 | 2026-03-06 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $431.94 | -1,663 | 161.8K | -1% | -$718.3K |
| D | 2026-03-06 | 2026-03-04 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +18.7K | 18.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-04 | A | A | 14,995 | $0.00 | 163,492 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-06 | S | D | 1,663 | $431.94 | 161,829 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-03-04 | A | A | 18,743 | $0.00 | 18,743 | D | $434.80 · — to 2036-03-04 | 18,743 Common Stock | (F3) The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |